Skip to main content
OpenTrials
Completed

NCT Number: NCT02068755

Blood Products in Cardiac Surgery

Blood transfusion is a common procedure essential for the treatment of patients undergoing cardiac surgery. Inappropriate transfusions, however, not only incur needless healthcare costs, but increase unnecessary risks due to transfusion reactions and infectious and immunomodulative causes. Safe and appropriate patient care requires evaluated blood component prescription practices.

Practically all patients undergoing cardiac surgery in Finland have a blood product booking from the Finnish Red Cross Blood Service. This registry contains large volumes of transfusion-related information on all Finnish patients undergoing cardiac surgery in Finnish centers. Participating hospitals were scattered to all geographical areas in Finland and concentrated to the most populated regions.

Data on the blood product use, laboratory findings one month pre-operatively and 12 months post-operatively were available.

Finnish hospitals have been required to provide information on hospital visits for the Finnish National Research and Development Centre for Welfare and Health for healthcare planning purposes. We used in part the original data sent by hospitals to the Finnish Hospital Discharge Register (FHDR).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Anemia Blood Platelet Disorders Cytopenia Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Hematologic Diseases Hemic and Lymphatic Diseases Kidney Diseases Male Urogenital Diseases Renal Impairment Renal Insufficiency Thrombocytopenia Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Registry includes

  • >21 000 patients who underwent coronary bypass,
  • >4500 patients with aortic valve replacement,
  • >4000 mitral valve operation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Cardiac surgery performed in Finnish University and Central hospitals
  • Blood product booking for surgery

Exclusion criteria

-

Treatment and study plan

Primary outcomes

  1. Red blood cell infusions

    Time frame: 12 months

  2. Platelet infusion

    Time frame: 12 months

  3. Fresh frozen plasma

    Time frame: 12 months

  4. Octaplas

    Time frame: 12 months

Secondary outcomes

  1. All cause mortality

    Time frame: 12 months

  2. myocardial infarction

    Time frame: 12 months

  3. TIA/stroke/arterial embolism

    Time frame: 12

  4. re-operation due to bleeding

    Time frame: 12 months

Sponsors and collaborators

Lead sponsor

University of Turku

Other

Collaborators

  • Central Finland Hospital District
  • Finnish Red Cross Blood Service
  • Helsinki University Central Hospital
  • Kuopio University Hospital
  • Oulu University Hospital
  • Satakunta Central Hospital
  • Tampere University Hospital
  • Turku University Hospital

Registry information

Official study title

The Use of Blood Products in Patients Undergoing Cardiac Surgery

Acronym: BiCS

Important dates

Study start
2002
Primary completion
2012
Study completion
2012
First posted
Feb 21, 2014
Registry last updated
Feb 21, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.